TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21999189
Drug: Single-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose group (40 mg/Kg TA before CPB and placebo after CPB)
Study: 21999189
Drug: Double-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose group (TA2)
Study: 21999189
Drug: Double-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose group
Study: 18192495
Drug: True iontophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: True iontophoresis (TI) with a 40‐mA/min dose of iontophoresis using a 0.4% (4 mg/mL) solution of dexamethasone
Study: 10728173
Drug: Venlafaxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75 mg/day) plus CBT
Study: 10728173
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/day) plus CBT
Study: 8554391
Drug: Flurbiprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (150 mg IM)
Study: 8554391
Drug: Dipyrone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (2 gm) + Hyoscine N-butylbromide (20 mg)
Study: 1952859
Drug: Furazolidone at
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone at 7 mg/kg/day once
Study: 1952859
Drug: Furazolidone at
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone at 7 mg/kg/day divided into four doses for 3 days
Study: 7037012
Drug: Beclobrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclobrate (100 mg twice daily)
Study: 7037012
Drug: Eniclobrate (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eniclobrate (130 mg twice daily)
Study: 31504390
Drug: General verbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: General verbal information on orthodontic treatment
Study: 22951488
Drug: Daily controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily controls with CBCT
Study: 22951488
Drug: Daily controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily controls with fiducial markers
Study: 22951488
Drug: Weekly controls
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly controls with CBCT
Study: 22951488
Drug: Weekly controls
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly controls with fiducial markers
Study: 22951488
Drug: Daily controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily controls compared to PI with CBCT
Study: 22951488
Drug: Daily controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily controls compared to PI with fiducial markers
Study: 19652059
Drug: Pomalidomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (2 mg/d) plus placebo
Study: 19652059
Drug: Pomalidomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (2 mg/d) plus prednisone
Study: 19652059
Drug: Pomalidomide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (0.5 mg/d) plus prednisone
Study: 19652059
Drug: Pomalidomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (2 mg/d) plus placebo (n = 62 patients receiving > or = 3 cycles)
Study: 19652059
Drug: Pomalidomide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (2 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Study: 19652059
Drug: Pomalidomide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (0.5 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Study: 19652059
Drug: Pomalidomide therapy
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide therapy (0.5 or 2 mg/d) with or without prednisone
Study: 14712348
Drug: Intralipid and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid and heparin (study ii)
Study: 14712348
Drug: Intralipid and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid and heparin combined with 20% dextrose (study iv)
Study: 10730110
Drug: 330 mL
Normalized name: ALCOHOL 247.5 mL in 330 mL EXTRACORPOREAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mL beer (containing about 20 g ethanol)
Study: 9135531
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements during inpatient phase
Study: 9135531
Drug: Oral dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dietary supplements during outpatient phase
Study: 1901332
Drug: Recombinant interferon-gamma
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon-gamma (rIFN-gamma) therapy
Study: 7041652
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 gm each)
Study: 25824424
Drug: Escitalopram, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Sertraline, Venlafaxine-XR (SSRIs and SNRIs)
Study: 17048428
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin B6 (50 mg), vitamin B12 (1 mg), and folic acid (15 mg) daily for 6 months
Study: 17048428
Drug: Oral 5
Normalized name: Syringe Oral 5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5 mg folic acid alone for 6 months
Study: 17048428
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral vitamin B6, vitamin B12, and folic acid
Study: 12612510
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water injection
Study: 8689841
Drug: Insulin-induced hypoglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycaemia (blood glucose 2.5 ± 0.4 mmol l-1 for 62 ± 8 min)
Study: 30264480
Drug: Insulin-induced hypoglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycaemia
Study: 6660476
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg/70 kg
Study: 6660476
Drug: flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam 1 mg/70 kg
Study: 6660476
Drug: fentanyl 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 0.15 mg/70 kg
Study: 27733571
Drug: Alemtuzumab 12
Normalized name: alemtuzumab 12 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab 12 mg
Study: 30785358
Drug: Alemtuzumab 24
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab 24 mg
Study: 30785358
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta‐1a (control)
Study: 29148881
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg of buprenorphine
Study: 29148881
Drug: 64 mg
Normalized name: sulfur 64 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg of buprenorphine
Study: 29148881
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg of buprenorphine
Study: 26422298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5 mg and mirabegron 25 mg
Study: 26422298
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5 mg and mirabegron 50 mg
Study: 19173747
Drug: Usual exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual exercise prescription (without preferences questionnaire)
Study: 17929306
Drug: CPG 10101
Normalized name: CPG 10101
DrugBank: CPG 10101 (DB05530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 10101 at 0.75 mg/kg SC once weekly for 4 weeks
Study: 17929306
Drug: CPG 10101
Normalized name: CPG 10101
DrugBank: CPG 10101 (DB05530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG 10101 (doses >/= 1 mg)
Study: 12492614
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (75 mg kg‐1 day‐1, 25 mg kg‐1 every 8 h)
Study: 9816718
Drug: ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 0.1 mg/kg
Study: 2572184
Drug: Rapid bolus
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid bolus injection of vecuronium bromide (0.015 mg/kg)
Study: 2572184
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of vecuronium bromide (0.015 mg/kg) over 5 min
Study: 52050
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and plasminogen infusion
Study: 52050
Drug: Streptokinase infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase infusion only (Control)
Study: 23701274
Drug: Benfotiamine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (900 mg/day for 6 weeks)
Study: 22178840
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment for sites with PD≥4 mm
Study: 16252275
Drug: Applications to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applications to a data set from a cocaine treatment study
Study: 15209771
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (60, 90, 120, 150 U)
Study: 15209771
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) injected regular human insulin (8, 14, or 20 U)
Study: 11424544
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ginseng
Study: 11424544
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ginseng
Study: 29650205
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution gargling
Study: 27986077
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support with weekly home-visits
Study: 27986077
Drug: First-line ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line ART regimens according to the National Treatment Guidelines (Control)
Study: 20872115
Drug: Extracorporeal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal high frequency thermotherapy (EHFT) combined with Chinese medicine (CM)
Study: 20872115
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) only
Study: 15635110
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (80 mg of atorvastatin orally per day)
Study: 15635110
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment (40 mg of pravastatin orally per day)
Study: 8543970
Drug: Intravenous PCNU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCNU
Study: 2135030
Drug: Subcutaneous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous PCA with oxymorphone
Study: 2135030
Drug: Subcutaneous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous PCA with morphine
Study: 2135030
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with oxymorphone
Study: 2135030
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with morphine
Study: 365313
Drug: Cyclophosphamide (800-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (800-1200 mg/m2 iv q 3 weeks)
Study: 365313
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Adriamycin (30-50 mg/m2 iv Day 1), 5-Fluorouracil (400-500 mg/m2 iv Day 1, 8), and Cyclophosphamide (150-200 mg/m2 po Day 3-6)
Study: 29133942
Drug: ns1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ns1 gene (100 µg)
Study: 29133942
Drug: vp3 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: vp3 gene (100 µg)
Study: 29133942
Drug: ns1 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ns1 + vp3 gene combination (100 µg each)
Study: 29133942
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (base values before therapy)
Study: 25384968
Drug: Orthogonal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthogonal injection of 0.05 mL of bevacizumab
Study: 25384968
Drug: Oblique injection
Normalized name: Inonotus obliquus fruiting body
DrugBank: Inonotus obliquus fruiting body (DB14332)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oblique injection of 0.05 mL of bevacizumab
Study: 1731289
Drug: Oral sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulindac for 48 hours
Study: 1731289
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin for 48 hours
Study: 2862318
Drug: Indirect fluorescent
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect fluorescent antibody (IFA) test
Study: 29020818
Drug: Juvenile Justice
Normalized name: Justicia spicigera leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juvenile Justice Anger Management (JJAM) Treatment for Girls
Study: 19967530
Drug: 0.6-g/kg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6-g/kg dose of ethanol
Study: 17009633
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - Group 1 (first dose)
Study: 17009633
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - Group 2 (second dose)
Study: 14558587
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 1.5 mg/kg injected over 2 minutes with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Study: 14558587
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo solution with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Study: 14558587
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol with propofol.
Study: 11140428
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) via Metered-Dose Inhaler (MDI)
Study: 9547133
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg single dose, followed by 150 mg three times a day for 4 weeks)
Study: 28763434
Drug: 20% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% mannitol (5 mL/kg infusion for 15 minutes)
Study: 28763434
Drug: 3% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hypertonic saline (5 mL/kg infusion for 15 minutes)
Study: 22492768
Drug: Detailed descriptions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detailed descriptions, CC presented first
Study: 22492768
Drug: Brief descriptions,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief descriptions, CC presented first
Study: 20802056
Drug: Unilateral TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral TAP block with ropivacaine (2.5 mg · kg(‐1) ropivacaine 0.75%)
Study: 19166424
Drug: RLF (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLF (20 mg rabeprazole, 500 mg levofloxacin, 200 mg furazolidone once daily for 10 days)
Study: 19166424
Drug: RBDF (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBDF (20 mg rabeprazole, 120 mg bismuth subcitrate, 100 mg doxycycline, 200 mg furazolidone twice daily for 10 days)
Study: 17374039
Drug: lamotrigine 25
Normalized name: lamotrigine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamotrigine 25 mg QID
Study: 17374039
Drug: memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine 10 mg TID
Study: 17374039
Drug: topiramate 25
Normalized name: topiramate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: topiramate 25 mg QID
Study: 17374039
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg TID
Study: 9331129
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with paclitaxel 175 to 225 mg/m2 and carboplatin (target AUC of 7.5) followed by G-CSF priming for 5 days before treatment.
Study: 9331129
Drug: Combined-modality treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality treatment (induction followed by concurrent thoracic radiation and chemotherapy).
Study: 9331129
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment with escalated paclitaxel dose of 225 mg/m2 on days 1 and 22 after initial patients accrued.
Study: 9331129
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic radiation and chemotherapy.
Study: 9331129
Drug: Concurrent thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent thoracic radiation and chemotherapy with esophageal exposure.
Study: 8164452
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with prednimustine (60 mg daily)
Study: 8164452
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with prednimustine (200 mg daily for five days every two weeks)
Study: 8164452
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with prednimustine
Study: 8164452
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with prednimustine
Study: 3746457
Drug: L-methionine
Normalized name: L-Methionine
DrugBank: Methionine C-11 (DB17147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine
Study: 3746457
Drug: L-methionine-dl-sulfoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine-dl-sulfoxide
Study: 30405294
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg PO)
Study: 26186880
Drug: bismuth‐containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth‐containing quadruple therapy (BCQT)
Study: 26186880
Drug: bismuth‐containing levofloxacin‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth‐containing levofloxacin‐based triple therapy (CBS‐LAL)
Study: 26186880
Drug: bismuth‐containing clarithromycin‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth‐containing clarithromycin‐based triple therapy (CBS‐LAC)
Study: 20888992
Drug: Cabazitaxel plus
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel plus prednisone (25 mg/m2 cabazitaxel intravenously over 1 h every 3 weeks)
Study: 20888992
Drug: Mitoxantrone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone plus prednisone (12 mg/m2 mitoxantrone intravenously over 15-30 min)
Study: 18377099
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of Vitamin D supplementation (55-70 ng per mL)
Study: 18377099
Drug: Pharmacological doses
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological doses of Vitamin D (2,000 IU per kg per day for three days)
Study: 10226868
Drug: Doxazosin standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin standard 1-8 mg once daily
Study: 31722690
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids), 10 sessions
Study: 31722690
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) intervention (Cool Kids)
Study: 25268286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Strength and Flexibility (ST + FLEX)
Study: 25268286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Flexibility and Strength (FLEX + ST)
Study: 21352389
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with citalopram
Study: 21352389
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with reboxetine
Study: 21352389
Drug: Exclusive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusive treatment with psychotherapy
Study: 18045825
Drug: ISN/RPS class
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISN/RPS class IV‐S and IV‐G
Study: 16925808
Drug: Aspirin (81-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81-100 mg/day)